SGLT2 inhibitor use may help stabilize eGFR levels for patients with autosomal dominant polycystic kidney disease and type 2 diabetes, according to study data.“Given its unique pathophysiology, ...

Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J Endocrinol Metab. 2018 May-Jun;22(3):421-428. doi: 10.4103/ijem.IJEM_585_17. Newsletter.

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a ...

van Aerts RMM, et al. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry. Liver international. 2019;39(3):575-82.

Six out of 10 people with type 2 diabetes had fatty liver in a new study from Linköping University. Of these, only a small percentage had developed more severe liver disease.

Traditionally used to treat type 2 diabetes, participants diagnosed with a life-threatening form of liver disease were given the injection. millaf – stock.adobe.com ...

Researchers believe that insulin resistance may play a role in the link between polycystic ovary syndrome (PCOS) and type 2 diabetes. Estimates of PCOS prevalence vary widely.

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a ...

van Keimpema L., et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver international. 2011;31(1):92-8.

Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients. Wednesday, June 18, 2025 Genetics & Stem Cells News. Advertisement PR Newswire ...